NCT Number: NCT00258947
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
Primary Objective:
To estimate the smallpox vaccination take rate in healthy young adults not previously vaccinated with a smallpox vaccine.
Secondary Objectives:
To describe antibody response to vaccination and evaluate the take for each subject at various timepoints for each batch and pooled batches and to evaluate local signs, symptoms, and overall safety in healthy young adults not previously vaccinated with a smallpox vaccine.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–25 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Gières, France
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Aged 18 to 25 years on the day of screening
- Informed consent form signed
- Able to attend all scheduled visits and to comply with all trial procedures
- For a woman, inability to bear a child or negative serum pregnancy test performed at screening (Visit 01)
- Subject entitled to national social security
- Subject registered in the French file of healthy volunteers in clinical trials
- For a woman of child-bearing potential: use of an effective method of contraception (hormonal or barrier method) from at least 3 months prior to screening to 3 months following trial vaccination
- For a woman, inability to bear a child or negative urine pregnancy test.
Exclusion criteria
- Previous smallpox vaccination confirmed by vaccination record or typical scar
- Participation in another trial in the 3 months before or during the trial period
- Acute intercurrent or chronic illness during the trial
- Breast-feeding
- Allergy or sensitivity to any known components of vaccinia immune globulin or previous reaction to immunoglobulins or trial vaccine
- Congenital or acquired immunodeficiency or immunosuppressive therapy or any treatment including corticosteroids
- Treatment with antiviral drugs within 1 month before vaccination
- History of organ or bone marrow transplant or skin disorders
- Personal or family history of autoimmune disease or cardiac disease, including cardiac risk factors
- History or current central nervous system disease
- Ongoing acute infectious disease
- Blood or blood-derived products received in the past 6 months
- Any vaccination with a live-attenuated vaccine within the 60 days or other vaccines within 40 days preceding the trial vaccination
- Vaccination planned in the 8 weeks following the trial vaccination
- Planned or foreseeable close contact after vaccination with infants less than 12 months, or with immuno-suppressed persons, pregnant and/or lactating woman, or practice of contact or water sports after vaccination before the crust separates
- Skin wound near the vaccination site
- Apparent lack of personal hygiene
- Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
- HIV, hepatitis B or hepatitis C seropositivity (screening tests)
- Abnormal lab values for hematological parameters or cardiac enzyme (screening tests)
- Feverish illness (oral temperature >=37.5°C, rectal equivalent temperature >=38.0°C) on the day of vaccination.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Sanofi
Industry
Registry information
Official study title
Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults.
Important dates
- Study start
- 2005
- Primary completion
- 2006
- Study completion
- 2007
- First posted
- Nov 28, 2005
- Registry last updated
- Feb 1, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.
NCT07377175
Animal Diseases, Cowpox
Hangzhou, China
View Trial DetailsA Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
NCT07379580
Animal Diseases, DNA Virus Infections
Kinshasa, Democratic Republic of the Congo
View Trial DetailsMVA Post-Event: Administration Timing and Boost Study
NCT00437021
DNA Virus Infections, Infections
Iowa City, Iowa, United States
View Trial DetailsA Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
NCT05995275
Animal Diseases, DNA Virus Infections
Bradford, United Kingdom
View Trial Details